Revolution Medicines COO Executes 10(b)(5)(1) Plan: Buys Low, Sells High in $1.6M Insider Trade Flash.
Insightful look at Revolution Medicines’ COO Margaret Horn’s 10(b)(5)(1) trades shows a balanced buy‑low, sell‑high strategy that signals insider confidence in its oncology pipeline while managing liquidity.
3 minutes to read
